Pharvaris ^None

Pharvaris is a clinical-stage company that aims to provide an oral bradykinin B2 receptor antagonist to patients with hereditary angioedema (HAE) and other B2 receptor-mediated indications. Their lead drug candidate, PHA121, is a small-molecule bradykinin B2 receptor antagonist that is currently undergoing Phase 1 clinical study. The company's co-founders have experience in developing icatibant, a drug for treating HAE, which is now sold by Takeda under the name Firazyr\xae.